Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oncology Institute, Inc. Director's Dealing 2024

May 24, 2024

33304_dirs_2024-05-23_57733808-eb59-4eeb-a393-feaa86d92354.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncology Institute, Inc. (TOI)
CIK: 0001799191
Period of Report: 2024-05-21

Reporting Person: Shah Mihir (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-05-21 Common Stock A 151459 $0.0 Acquired 474931 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-05-21 Non-Qualified Stock Option (right to buy) $2.0 A 378648 Acquired 2034-05-21 Common Stock (378648) Direct

Footnotes

F1: Represents RSUs with 1/4th of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

F2: Amount includes a reduction of 4,650 shares from the prior filing, as it corrects an inadvertent overstatement of holdings due to clerical error.

F3: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.